Magadh Sugar (MAGADSUGAR)
Asset PlayFairStock Score: 36/100 — MIXED
Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 1/1
Key Financials
| Current Price | ₹543.3 |
| Market Cap | ₹765.6 Cr |
| P/E Ratio | 14.99 |
| ROCE | 12.7% |
| ROE | 11.66% |
| Dividend Yield | 2.3% |
| Profit Growth | -999% |
| Debt/Equity | 0.79 |
| Sales Growth | -6.99% |
| Promoter Holding | 61.02% |
| 52-Week Range | ₹417 — ₹635 |
| Sector | Agricultural Food & other Products |
| Book Value | ₹624.62 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Magadh Sugar catches my eye for one simple reason: I am paying ₹526 for每 rupee of book value worth ₹536. That’s a P/B of 0.98, essentially buying the company at a slight discount to what its net assets are worth. The P/E of 7.39 and PEG of 0.52 suggest the market is giving this sugar business little credit for its recent profit growth of 23.92%. But let’s be honest with ourselves — sugar is a commodity, and I don’t like businesses where the product is the same as everyone else’s. There is no real moat here; the earnings are at the mercy of sugar prices, monsoon cycles, and government policy. The sales growth of only 4.43% confirms this is not a growth machine. Still, the balance sheet is decent: debt-to-equity of 0.41 and a Piotroski F-Score of 7/9 indicates the company is financially healthy and not faking its numbers. The 61% promoter holding aligns interests, and a 2.72% dividend yield gives me some payback while I wait. At 8 times trailing earnings, the market has already priced in a lot of pessimism. But I must remind myself: a cheap cyclical can become cheaper. I would call this a solid cyclical asset play, not a compounding stalwart. If sugar prices remain firm and profits hold, the stock is undervalued. If the cycle turns, the book value offers some cushion, but I won’t mistake a commodity producer for a franchise.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer